Simplifying factor VIII reconstitution may increase treatment adherence and satisfaction in patients with hemophilia A.
Unnecessarily high platelet count thresholds may expose patients undergoing lumbar or epidural procedures to excessive transfusion-related risks.
Gene therapy with adeno-associated viral viruses could provide an efficacious, safe, and cost-effective treatment option for patients with hemophilia.
Researchers conducted a retrospective chart review to assess the bleeding risk associated with gastrointestinal endoscopy.
Researchers assessed potential risk factors for major bleeding in patients without cardiovascular disease to develop sex-specific prediction models.
Researchers assessed whether prophylactic treatment with von Willebrand factor/factor VIII concentrates reduced bleeding risk.
Population-based screening of newborns is crucial to identifying severe combined immunodeficiency before the onset of potentially fatal infection.
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of patients with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes and perioperative management of bleeding.
Underlying lymphoproliferative syndromes, male gender, and older age may be predictive of relapse in patients with acquired hemophilia A.
Researchers assessed safety outcomes in patients with hemophilia A without inhibitors.
Several factors need to be considered when determining whether a child’s bleeding symptoms are the result of a coagulation disorder, physical abuse, or both.
Researchers assessed the influence of adopting population pharmacokinetics to inform prophylaxis for patients with hemophilia A.
Acute major bleeding decreased by 92% in patients who were treated with andexanet alfa.
Using rotational thromboelastometry may allow assessment of bleeding risks in patients with clinically relevant von Willebrand disease.
Researchers conducted the first real world study to compare the safety and effectiveness of apixaban and rivaroxaban in patients with VTE.
Changes in clinical management of trauma hemorrhage have significantly reduced mortality rates, but variation in treatment strategies still remains.
The need for tranexamic acid to be administered intravenously creates a barrier to rapid treatment of patients with fibrinolysis.
Many unique challenges surround the diagnosis and treatment of inherited mild bleeding disorders.
The interactions between von Willebrand factors and its cleaving protease ADAMTS-13 recently emerged as risk factors for pediatric thromboembolism.
Propensity for bleeding was previously thought to relate to greater fibrinolytic activity, but this may not be the case.
Accurate measurement of low factor VIII levels is necessary for proper monitoring of factor VIII replacement therapy.
Clot waveform analysis of the Clauss fibrinogen assay may allow classification of fibrinogen disorders without measuring fibrinogen antigen levels.
Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or uncontrolled bleeding.
The indication has been changed from “control and prevention of bleeding episodes” to “on-demand treatment and control of bleeding episodes” in adults and children with hemophilia A.
Aminocaprioc Acid Tablets are useful in enhancing hemostasis when fibrolysis contributes to bleeding.
Research presented at the 2018 ASH Annual Meeting provided insights into the role of factor VIII as a therapeutic agent for severe hemophilia A.
Andexanet alfa is the first anticoagulant reversal agent to receive global US FDA approval for patients with life-threatening or uncontrolled bleeding.
Researchers comment on the implications of treating newborns and infants with von Willebrand factor (VWF) concentrate.
A review of the management and outcomes for patients with autoimmune Factor V (FV) inhibitors.
Residual plasma levels of clotting factor XIII or factor IX accounted for around 70% of bleeding phenotype in patients with clinically severe hemophilia.
The expanded approval was based on data from two Phase 3 clinical trials: HAVEN 3 and HAVEN 4.
The approval was supported by data from the phase 2/3 international, open-label PROTECT VIII trial (N=126) that evaluated previously treated patients aged ≥12 years with severe hemophilia A.